June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Nicergoline: A Novel Treatment for Persistent Corneal Epithelial Defect
Author Affiliations & Notes
  • Valeria Oliva
    Cornea, Institute of Ophthalmology "Conde de Valenciana", CDMX, Mexico
  • Jesus Cabral
    Cornea, Institute of Ophthalmology "Conde de Valenciana", CDMX, Mexico
  • Juan Carlos Serna-Ojeda
    Cornea, Institute of Ophthalmology "Conde de Valenciana", CDMX, Mexico
  • Victor Boullosa
    Cornea, Institute of Ophthalmology "Conde de Valenciana", CDMX, Mexico
  • Arturo J Ramirez-Miranda
    Cornea, Institute of Ophthalmology "Conde de Valenciana", CDMX, Mexico
  • Alejandro Navas
    Cornea, Institute of Ophthalmology "Conde de Valenciana", CDMX, Mexico
  • Enrique O Graue-Hernandez
    Cornea, Institute of Ophthalmology "Conde de Valenciana", CDMX, Mexico
  • Footnotes
    Commercial Relationships   Valeria Oliva, None; Jesus Cabral, None; Juan Carlos Serna-Ojeda, None; Victor Boullosa, None; Arturo Ramirez-Miranda, None; Alejandro Navas, None; Enrique Graue-Hernandez, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 172. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Valeria Oliva, Jesus Cabral, Juan Carlos Serna-Ojeda, Victor Boullosa, Arturo J Ramirez-Miranda, Alejandro Navas, Enrique O Graue-Hernandez; Nicergoline: A Novel Treatment for Persistent Corneal Epithelial Defect. Invest. Ophthalmol. Vis. Sci. 2017;58(8):172.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Purpose: The aim of this study was to determine the effect of nicergoline in patients with persistent corneal epithelial defect.

Methods : Methods: This is a retrospective analysis, of consecutive case series. The study included 10 eyes of 9 patients with persistent corneal epithelial defect unresponsive to conventional therapy. Patients were treated with 10 mg nicergoline orally twice a day for at least 2 weeks. Slit-lamp examination, photography, corneal fluorescein dye testing, and best- corrected visual acuity were performed before and after treatment.

Results : Results: Two male and seven female patients with persistent corneal epithelial defect unresponsive to conventional therapy treated with oral nicergoline were included. Average age was 60.9 years (51-76 years). The most frequent diagnoses associated with persistent corneal defect were neurotrophic (3 patients) and exposure ulcer (2 patients). In eight eyes (72.7%), epithelial defects healed completely between 10 and 28 days of treatment with nicergoline (mean resolution time17 days). Epithelial defects persisted in 2 eyes (27.3%).

Conclusions : Conclusion: Nicergoline represents a potential therapeutic option in patients with abnormal corneal healing responses. Further studies and clinical trials need to be conducted to prove safety and efficacy as a treatment for persistent corneal epithelium defects in humans.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×